CSIMarket
 
Immuneering Corporation  (NASDAQ: IMRX)
 
Price: $4.4400 $0.11 2.540%
Day's High: $4.474999904632568 Week Perf: -3.69 %
Day's Low: $ 4.24 30 Day Perf: -12.25 %
Volume (M): 862,078 52 Wk High: $ 10.08
Volume (M$): $ 0 52 Wk Avg: $5.53
Open: $4.33 52 Wk Low: $3.86



 Market Capitalization (Millions $) 287
 Shares Outstanding (Millions) 65
 Employees 53
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -57
 Cash Flow (TTM) (Millions $) 21
 Capital Exp. (TTM) (Millions $) 0

Business Description


Immuneering Corp is a biotechnology company that specializes in developing computational tools for drug discovery and precision medicine. It was founded in 2008 by Ben Zeskind and Harvard professor Mark Namchuk in Cambridge, Massachusetts.

The companyes main focus is to develop technology that can help identify new therapeutic targets and optimize drug development processes. The technology works by integrating vast amounts of data from various sources, including genomic, proteomic, and clinical data, to create a comprehensive understanding of disease biology.

Immuneering Corpes platform is built on proprietary algorithms and machine learning techniques that can analyze large and complex datasets. They use these tools to identify patterns and relationships that can help uncover the underlying mechanisms of disease and identify new drug targets.

The companyes technology is applicable across a wide range of therapeutic areas, including oncology, immunology, neurodegenerative diseases, and infectious diseases. Its clients include leading pharmaceutical and biotechnology companies as well as academic research institutions.

One of Immuneering Corpes unique offerings is their ability to identify mechanisms of drug resistance, which is a major challenge in drug development. They use their technology to analyze large patient datasets to identify why some patients do not respond to certain drugs, and use this information to identify new drug targets or optimize treatment regimens.

As of 2021, Immuneering Corp has raised over $117 million in funding from investors such as Omega Funds, Boxer Capital, and MiraeAsset. The company has also formed several strategic partnerships with leading pharmaceutical companies, including AbbVie and Sanofi.


   Company Address: 245 Main St Cambridge 2142 MA
   Company Phone Number: 500-8080   Stock Exchange / Ticker: NASDAQ IMRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
MDGL   -2.78%    
RYTM   -4.94%    
SUPN   -2.71%    
TGTX   -4.84%    
ZLAB   -2.48%    
ZYME   -7.99%    
• View Complete Report
   



Clinical Study

Advancements in First-Line Pancreatic Cancer Treatment A Comprehensive Overview of Immuneering’s Clinical Developme...

Published Wed, Sep 10 2025 11:45 AM UTC

Pancreatic cancer remains one of the most formidable challenges in oncology, characterized by its aggressive nature and high mortality rates. In recent years, innovation in therapeutic strategies has gained momentum, with various candidates emerging from clinical trials. Among these, Immuneering Corporation, a biotechnology company focused on drug discovery and development,...

Management Announcement

Amid Financial Hurdles, Immuneering Pursues Hope in the Fight Against Pancreatic Cancer,

Published Tue, Dec 17 2024 1:00 PM UTC

Immuneering s Bold Move in Pancreatic Cancer Treatment Amid Financial ChallengesIn a high-stakes environment where the pharmaceutical industry is often fraught with both promise and peril, Immuneering Corporation s recent announcements have sparked a wave of enthusiasm and concern. The Cambridge-based biotech firm is on the precipice of critical data presentations and has ...

Clinical Study

Immuneering Secures Orphan Drug Designation for IMM-1-104 in Groundbreaking Pancreatic Cancer Therapy

Published Tue, Oct 15 2024 12:01 PM UTC

Immuneering s Significant Milestone: Orphan Drug Designation for IMM-1-104 in the Fight Against Pancreatic Cancer In a notable advancement for the treatment of one of the most aggressive forms of cancer, Immuneering Corporation has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its innovative therapeutic candidate, IMM-1-104. This dist...

Clinical Study

Immuneering Reports Promising Phase 2a Data for IMM-1-104 in Combination with Chemotherapy in First-Line P...

Published Thu, Sep 12 2024 8:05 PM UTC

In a remarkable stride towards transforming pancreatic cancer therapies, Immuneering Corporation has unveiled positive initial data from its Phase 2a clinical trial of IMM-1-104. This investigational agent, in synergy with chemotherapy, is being tested as a first-line treatment for patients struggling with this aggressive and notoriously difficult-to-treat malignancy. The fi...

Clinical Study

Immuneerings IMM-1-104 Receives FDA Fast Track Designation, Pioneering Treatment for First-line Pancreatic Cancer

Published Wed, Jul 31 2024 8:05 PM UTC

In a significant development for the treatment of pancreatic cancer, Immuneering Corporation has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, IMM-1-104. This designation is particularly noteworthy as it accelerates the clinical development of medications attending to serious conditions that fill an unmet medic...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 1.51
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.14
Working Capital Ratio 19.47
Leverage Ratio (MRQ) 0.06
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.12 $
Revenues (TTM) -
Cash Flow (TTM) 0.32 $
Cash 0.65 $
Book Value 2.95 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,080,683
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.